PYOTT DAVID E I 4

What Happened
David E. I. Pyott, a director of Alnylam Pharmaceuticals (ALNY), received equity awards on May 20, 2026: 671 restricted stock units (RSUs) and 1,441 derivative shares (a grant tied to a stock option or similar award). Both grants show an acquisition price of $0 (typical for compensation grants); no cash proceeds or open‑market trades were reported.

Key Details

• Transaction date: May 20, 2026; Form 4 filed May 22, 2026 (appears timely).
• Grants: 671 RSUs @ $0.00; 1,441 derivative shares @ $0.00.
• Shares owned after transaction: not specified in the provided summary.
• Footnotes of note:
  • F1: The 671 RSUs represent contingent rights to one share each; they vest in full on the earlier of the first anniversary of grant or certain earlier retirement/resignation (if within 90 days prior to the first anniversary).
  • F3: The derivative award (stock option/related instrument) vests in full on the earlier of the first anniversary of grant or certain earlier retirement/resignation (same 90‑day condition).
  • F2: Separately, some ALNY common stock was purchased by the David E I Pyott Trust, of which Mr. Pyott is trustee (reported in the filing notes).
• Transaction code: A (award/grant) — not a purchase (P) or sale (S).

Context

• These entries are compensation awards rather than open‑market purchases or sales; awards are common for directors and reflect compensation, not an immediate market bet.
• The derivative award is subject to a vesting condition rather than an exercise/sale; no sale or cashless exercise was reported.
• For retail investors, awards signal company compensation activity but do not necessarily indicate the insider’s short‑term view on the stock.